Although several biomarkers show promise, PCA3 has garnered substantial attention following FDA approval and its role in the diagnosis of PCa will grow.
The University of Michigan Health System is offering a new urine test called Mi-Prostate Score to improve on PSA screening.
Both web-based and print-based decision aids appear to improve patient's informed decision making about prostate cancer screening.
Elevated urinary levels of the organic compound were found in men with prostate cancer than in those without it.
High PSA and short PSA double time are associated with a greater likelihood of a positive bone scan.
Additional predictors guide selection of patients for active surveillance programs.
New nomogram could help clinicians and patients make treatment decisions.
TPTPB should be regarded as the gold-standard test in men with two sets of negative TRUS-guided biopsies and rising PSA levels, researchers say.
Texas study shows that PSA screening was ordered for 41% of men aged 75 and older, largely because of decisions by primary-care physicians.
Biopsy-related procedures accounted for much of the cost.
Relying on PSA doubling time from just one year of active surveillance can result in as many as one in five prostate cancer patients being advised to undergo curative treatment that may be unnecessary.
One year of PSA test results can lead to 10%-20% of men being misclassified as having a high risk of prostate cancer progression.
Print- and Web-based tools presenting the benefits and limitations of PSA testing served to help men resolve their own conflicts.
Findings support the notion of a link with sleep or circadian disruption.
Post-PSA intro, big drop in advanced-stage cancers but only modest drop in high Gleason score cancers.
PSA levels below 0.65 ng/mL provide the best sensitivity and specificity (65.2% and 55.5%, respectively) for predicting severe hypogonadism.
Findings based on survey even after informing men about the USPSTF recommendation.
The drug prolonged development of bone metastasis by a median of 7.2 months.